We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Circle Pharma has initiated a clinical trial to evaluate
the safety and efficacy of CID-078, as monotherapy
across a range of solid tumors.
This first-in-human, Phase 1, multi-center, open-label, dose-escalation, dose-expansion study is evaluating CID-078 in patients with advanced cancer. This study is being conducted in two parts. The primary purpose of Part 1 is to evaluate safety and identify one or more doses for expansion (Part 2). Part 2 will evaluate anti-tumor efficacy and further characterize the safety, tolerability, and pharmacokinetics of the CID-078 dose(s) selected in Part 1.
Visit ClinicalTrials.gov (NCT06577987) for more information about this trial.
CID-078 is an investigational agent whose safety and efficacy in solid tumor malignancies has not been evaluated by the FDA or any other regulatory Agency.
This site is intended for US residents only.
© 2024 Circle Pharma. All Rights Reserved.
